PubMed İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/11727/4810
Browse
14 results
Search Results
Item Recommendations for Ramadan Fasting to Patients with Cardiovascular Diseases; Turkish Society of Cardiology Consensus Report(2021) Alper, Ahmet Taha; Akboga, Mehmet Kadri; Ozcan, Kazim Serhan; Tengiz, Istemihan; Turk, Ugur Onsel; Yildiz, Mustafa; Yilmaz, Mehmet Birhan; Kayikcioglu, Meral; Gazi, Emine; Yildirir, Aylin; 33960303Item Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology(2020) Sahinarslan, Asife; Gazi, Emine; Sahinarslan, Asife; Gazi, Emine; Aktoz, Meryem; Ozkan, Cigdem; Okyay, Gulay Ulusal; Elalmis, Ozgul Ucar; Belen, Erdal; Bitigen, Atila; Derici, Ulver; Tutuncu, Neslihan Bascil; Yildirir, Aylin; 0000-0002-1816-3903; 0000-0001-8750-5287; 32870176; ABG-5027-2020; A-4947-2018Item 2020 ESC Core Curriculum for the Cardiologist: What has changed? Why? Should we also change our curriculum?(2020) Yildirir, Aylin; 0000-0001-8750-5287; 33257609; 33257609; A-4947-2018Item Turkish Society of Cardiology consensus report on recommendations for athletes with high-risk genetic cardiovascular diseases or implanted cardiac devices(2019) Ozel, Erdem; Kosar, Mustafa Feridun; Ozcan, Emin Evren; Hunuk, Burak; Ulus, Taner; Aytekin, Vedat; Yildirir, Aylin; Ozin, Bulent; Erdinler, Izzet; Akyurek, Omer; 0000-0001-8750-5287; 31475950; A-4947-2018Item The opinion and recommendations of Turkish Board for Accreditation in Cardiology on Board Examination(2019) Yildirir, Aylin; Altun, Armagan; Ural, Dilek; Ozdemir, Murat; Aslan, Ozgur; Muderrisoglu, Haldun; 31582681; ABB-5844-2020Item ADMA is a useful marker, but many confounding factors should be considered! Reply(2015) Bal, Ugur Abbas; Yildirir, Aylin; 25789383Item Assessment of serum hepcidin levels in patients with non-ST elevation myocardial infarction(2015) Okyay, Kaan; Yildirir, Aylin; 25625449Item The preanalytical and analytical factors responsible for false-positive cardiac troponins(2015) Okyay, Kaan; Yildirir, Aylin; 25880185Item Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography(2015) Yilmaz, Mustafa; Aydinalp, Alp; Okyay, Kaan; Tekin, Abdullah; Bal, Ugur Abbas; Bayraktar, Nilufer; Yildirir, Aylin; Muderrisoglu, Haldun; 26195972Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 +/- 1.48 to 8.38 +/- 2.6 nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 +/- 1.21 vs. 7.56 +/- 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN. (C) 2015 S. Karger AG, BaselItem The effect of raloxifene on left ventricular hypertrophy in postmenopausal women: A prospective, randomized, and controlled study(2015) Bal, Ugur Abbas; Atar, Ilyas; Oktem, Mesut; Zeyneloglu, Hulusi Bulent; Yildirir, Aylin; Kuscu, Esra; Muderrisoglu, Haldun; 25430415Objective: In healthy women, there is a progressive age-related increase in myocardial mass that is not seen in their male counterparts and occurs primarily in postmenopausal women. Raloxifene is a selective estrogen receptor modulator that has estrogenic actions on bone and the cardiovascular system. The aim of this study was to investigate the effect of raloxifene on myocardial hypertrophy in postmenopausal patients. Methods: A total of 22 postmenopausal osteoporotic women were included in this open-label, randomized, prospective, controlled study. Patients were randomized into two groups: 11 of the patients (group 1) were treated with raloxifene 60 mg/day, and the other 11 patients (group 2) were defined as the control group. Quantitative 2-dimensional and M-mode echocardiographic examination was performed in all patients at the beginning and repeated at the end of the 6-month follow-up period. Left ventricle mass (LVM) and left ventricle mass index (LVMI) were calculated for all patients. Results: The mean age of the patients was 57.2 +/- 3.9 years, and baseline clinical characteristics and echocardiographic parameters were similar between the two groups. After 6 months of raloxifene treatment, there was no difference in echocardiographic parameters of LVM and LVMI compared with the control group (201.2 +/- 25.9 gr vs. 169.7 +/- 46.2 gr, p=0.14 and 120.4 +/- 25.9 gr/m(2) vs. 105.5 +/- 26.3 gr/m(2), p=0.195, respectively). There was also no significant difference in LVM and LVMI in the within-group analysis of both groups. Conclusion: Raloxifene therapy does not affect myocardial hypertrophy in postmenopausal women after 6 months of treatment.